ERBB2 and ovarian carcinoma: Furthermore, in vivo delivery of αHer‐CrNC in a HER2‐positive ovarian cancer model could substantially suppress tumor growth, mediated by disruption of the plk1 gene and cellular apoptosis in the tumors.